Life Science Technical Accounting Update 2026 Registration Now Openvers Revenue Recognition, R&D Accounting, And Genai Automation Across 16 CPE Credit Hours
Dublin, Aug. 31, 2026 (GLOBE NEWSWIRE) -- The "Life Science Technical Accounting Update 2026 (Sept 16th - Sept 17th, 2026)" has been added to ResearchAndMarkets.com's offering.
Life Science Technical Accounting Update 2026: Virtual Conference for Finance and Accounting Professionals
The life science industry continues to experience rapid change as companies respond to new Accounting Standards Updates (ASUs), evolving revenue models, digital transformation, and increasingly complex financial reporting requirements. The Life Science Technical Accounting Update 2026 is a two-day virtual conference created to help finance and accounting professionals navigate these developments and strengthen reporting practices across biotechnology, pharmaceutical, and medical technology organizations.
Designed specifically for the accounting challenges facing life science companies, the conference will deliver focused guidance on significant technical accounting developments and their practical implications. Attendees will explore select ASUs relevant to the sector, including key implementation considerations, reporting timelines, and factors that may affect financial statements, disclosures, internal processes, and business decisions.
The program will move beyond a review of accounting standards by emphasizing practical application within complex life science operating environments. Sessions will address challenging revenue recognition matters, including issues influenced by changing commercial arrangements, collaboration structures, product development activities, and other industry-specific considerations. The agenda will help participants evaluate how current accounting requirements may apply to evolving business models and financial reporting responsibilities.
Artificial intelligence and digital transformation will also be central topics throughout the Life Science Technical Accounting Update 2026. Conference sessions will examine practical opportunities to incorporate AI and digital solutions into accounting and finance operations. Participants will gain insight into how emerging technologies may support more efficient workflows, improve data analysis, enhance reporting processes, and help finance teams manage increasing demands without compromising accuracy or oversight.
The virtual format provides accounting and finance professionals with convenient access to timely technical content while allowing them to participate from any location. Over two days, attendees can build their understanding of important accounting developments, assess potential implementation challenges, and identify practical approaches that may support stronger financial reporting across their organizations.
Learning Objectives:
- Understand the latest accounting developments and select ASUs most relevant to biotechnology, pharmaceutical, and medical technology companies. Identify key effective dates, implementation timelines, and reporting considerations affecting life science organizations. Evaluate industry-specific factors that may influence financial reporting, disclosures, accounting policies, and internal processes. Examine complex revenue recognition issues arising within life science business models and commercial arrangements. Gain practical insight into applying artificial intelligence and digital solutions across accounting and finance functions. Consider opportunities to enhance operational efficiency, data analysis, reporting quality, and financial decision-making through digital transformation.
The Life Science Technical Accounting Update 2026 is relevant for accounting, finance, financial reporting, controllership, and related professionals seeking specialized guidance for the life sciences sector. Whether preparing for upcoming accounting changes, addressing complex revenue recognition questions, or evaluating the role of AI in finance operations, participants will receive actionable insights aligned with current industry priorities.
Continuing Professional Education: Attendees can earn up to 16 CPE credits by participating in the two-day virtual conference.
Who Should Attend:
- CFOs (and their staff) Controllers VPs of Finance Financial Managers Internal Auditors Tax Accountants Treasury Staff Accountants in Industry Internal Control/SOX personnel Consultants Public Accountants Educators
Agenda:
Agenda: DAY 1
8:45-10:20 SEC & FASB Developments Affecting Life Science Companies
10:20-10:30 Break
10:30-11:45 Accounting for Convertible Debt
- New Guidance Questions to Consider Accounting Models
11:45-1:00 Lunch Break
1:00-2:10 GenAI Automation Update
2:10-2:20 Break
2:20-3:45 Financing Trends and Market Overview
- Royalty Monetization Convertible Debt Accounting Considerations When should companies consider convertible debt? Convertible structure in the life science financing cycle Changes of control, tax implications, size, maturity and other questions
3:45-3:55 Break
3:55-4:50 IT General Controls
Agenda: DAY 2
8:45-9:55 Revenue Recognition: Evolving Issues - Life Sciences
- Scope of Contract Performance Obligations Nature of promise: sales of points Collaboration agreements Sales using third party platforms Gross vs Net Counterparty Perspective
9:55-10:10 Break
10:10-11:30 Accounting for Financing Arrangements in Life Sciences
11:30-12:00 Break
12:00-1:30 Gross to Net
- Introduction and Overview Industry View Estimation Methodology Approaching Launch Key Challenges SEC Comments Close and Financial Reporting GTN Hot Topics Discussion Inventory Accounting Refresh
1:30-1:40 Lunch Break
1:40-2:40 Tax Update
- Latest legislative developments Key Tax Proposals Possible timing and other legislative priorities
2:40-2:55 Break
2:55-4:05 Accounting for R&D and Clinical Trials
- R&D Funding Arrangements R&D Cost Classifications Other Intangible Assets SEC Comment Letter Trends
4:05-4:15 Break
4:15-5:00 Value Based Care
- Guarantees and indemnifications Accounting challenges Revenue Recognition components
Speakers
Nathan Mitchell, Deloitte, Partner
Adam Barrow, Riveron, Senior Director
Nick Sanfilippo, Riveron, Director, Accounting Advisory & IPO
Ruchi Tiwari, Deloitte, Senior Manager
Ester Kutalchuk, Deloitte, Senior Consultant
Matt Norman, Deloitte, Manager
Russ Higgins, Connor Group, Partner
Travis Combs, Riveron, Managing Director
Marcus Lindner, Ernst & Young, Partner
Boyang Zhao, Riveron, Director, Accounting Advisory
Nathaniel Spedalieri, Ernst & Young, Senior Manager
Annie Wong, Ernst & Young, Assurance Senior Manager
Rucha Waghulde, Deloitte, Senior Consultant
Kyle Straub, PwC, Director
Moira Klinger, PwC, Director
Emma Nealis, PwC, Manager
Aleks Zabreyko, Connor Group, Managing Partner
Jeffrey Kummer, Deloitte, Director of Tax Policy
Joshua Areola, Ernst & Young, Assurance Senior Manager
Tim Geringer, Ernst & Young, Senior Manager
James Bowie, Ernst & Young, Managing Director, Technical Accounting Advisory Group
Spencer Moses, Ernst & Young, FAAS Manager
Tanner Schnitz, Ernst & Young, Technical Accounting Manager
James Bowie, Ernst & Young, Managing Director, Technical Accounting Advisory Group
Randa Ghantous, Connor Group, Partner
Matt Lepley, Connor Group, Partner
For more information about this conference visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment